About the Event
Antibody-drug conjugates (ADCs) combine the targeting capabilities of antibodies with the potent activity of cytotoxic payloads, creating unique analytical challenges throughout drug development. Robust bioanalytical strategies are essential for characterizing ADC binding properties and addressing critical challenges in pharmacokinetic (PK) assessment.
Highlights:
- Target and Fc receptor binding by SPR/BLI
- ADC PK challenges: DAR sensitivity and payload biotransformation
- Soluble target interference and ADA assessment
- Integrated bioanalytical solutions for ADC development
Hosted by
ACROBiosystems Industry Supporter
Supplies recombinant proteins, antibodies, assay kits, and critical reagents that support drug discovery, immunotherapy, vaccine development, and cell and gene therapy research.